P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Subrata Ghosh

doi:10.1093/ecco-jcc/jjac190.0683

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Subrata Ghosh

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Journal of Crohn's and Colitis
DOIs	https://doi.org/10.1093/ecco-jcc/jjac190.0683
Publication status	Published - 2023

Keywords

Medicine
Ustekinumab
Concomitant
Internal medicine
Psoriatic arthritis
Bristol-Myers
Tuberculosis
Inflammatory bowel disease
Ulcerative colitis
Gastroenterology
Surgery
Adalimumab
Disease
Pathology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ecco-jcc/jjac190.0683

https://openalex.org/W4318578194Licence: CC BY-NC-ND

Researcher from University College Cork Details Findings in Inflammatory Bowel Disease (P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications)
Ghosh, S.
10/02/23
1 item of Media coverage
Press/Media

Cite this

@article{c29545d279b74139b05580803f11e6e0,

title = "P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications",

keywords = "Medicine, Ustekinumab, Concomitant, Internal medicine, Psoriatic arthritis, Bristol-Myers, Tuberculosis, Inflammatory bowel disease, Ulcerative colitis, Gastroenterology, Surgery, Adalimumab, Disease, Pathology",

author = "Subrata Ghosh",

year = "2023",

doi = "10.1093/ecco-jcc/jjac190.0683",

language = "English",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

AU - Ghosh, Subrata

PY - 2023

Y1 - 2023

KW - Medicine

KW - Ustekinumab

KW - Concomitant

KW - Internal medicine

KW - Psoriatic arthritis

KW - Bristol-Myers

KW - Tuberculosis

KW - Inflammatory bowel disease

KW - Ulcerative colitis

KW - Gastroenterology

KW - Surgery

KW - Adalimumab

KW - Disease

KW - Pathology

U2 - 10.1093/ecco-jcc/jjac190.0683

DO - 10.1093/ecco-jcc/jjac190.0683

M3 - Article

SN - 1873-9946

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

ER -

P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications

Keywords

UN SDGs

Access to Document

Press/Media

Researcher from University College Cork Details Findings in Inflammatory Bowel Disease (P553 Active tuberculosis and opportunistic infections: Pooled safety analysis of ustekinumab through up to 5 years across all approved indications)

Cite this